samedan logo
 
 
spacer
home > pmps > spring 2017 > new thinking
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

New Thinking

When it comes to complacency, Albert Einstein once remarked: “If you always do what you always did, you will always get what you always got.” This very principle applies in healthcare and for today’s seven billion global consumers, who are living longer, have better access to quality care and are demanding more choices, greater convenience and improved outcomes.

It is an evolving paradigm, and delivering sophisticated, high-value pharmaceuticals to emerging markets will require continuous new thinking. The same supply chain issues will continue to pose steady challenges – cost and compliance chief among them – but leveraging cold chain innovations will produce significant gains in years to come.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jan Denecker is responsible for executing UPS’s healthcare strategy in Europe. He joined the company in 2011 as Marketing Manager of Healthcare and led the launch of the department in Europe. In 2014, Jan was appointed Marketing Manager of Belgium and Luxembourg, responsible for business planning, revenue management, marketing and communications in both countries. He holds a Master’s degree in Law from the Université catholique de Louvain, Belgium, and a Master’s degree in Business Administration from the Vlerick School of Management, Belgium.
spacer
Jan Denecker
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sanofi invests $180 million equity in Owkin’s artificial intelligence and federated learning to advance oncology pipeline

Sanofi announced today an equity investment of $180 million and a new strategic collaboration with Owkin comprised of discovery and development programmes in four exclusive types of cancer, with a total payment of $90 million for three years plus additional research milestone-based payments.
More info >>

White Papers

Outsourcing and Insourcing: How Eurofins solves the bio/pharma industry’s challenges associated with meeting drug development timelines and budgets with restricted headcounts

Eurofins BioPharma Product Testing

Pharmaceutical and biopharmaceutical companies face a significant challenge to get their drug products developed and launched quickly, all while keeping development costs down. One of the most common ways for companies to lower development costs is to manage fixed headcounts. But when the same scope of work still needs to be completed by a designated time with fewer staff members, this presents a significant challenge. So, how do bio/pharma companies solve this ever so common challenge of increasing output while decreasing headcount? There are essentially three options: temporary staffing, outsourcing, or insourcing.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement